

Stephen E Langabeer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5324277/publications.pdf>

Version: 2024-02-01

146
papers

2,531
citations

643344

15
h-index

223390

49
g-index

146
all docs

146
docs citations

146
times ranked

3240
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of atypical <i>BCR-ABL1</i> fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	0
2	Testosterone, erythrocytosis and the JAK2 V617F mutation. <i>Annals of Clinical Biochemistry</i> , 2022, , 000456322210778.	0.8	0
3	Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia. <i>Leukemia Research</i> , 2022, 116, 106823.	0.4	1
4	Screening for latent polycythemia vera in chronic obstructive pulmonary disease-associated erythrocytosis. <i>Respiratory Medicine and Research</i> , 2022, 81, 100914.	0.4	0
5	Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic. <i>Irish Journal of Medical Science</i> , 2021, 190, 27-28.	0.8	6
6	Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia?. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102521.	0.6	2
7	CALR Mutation Underlying Silent Stroke. <i>TH Open</i> , 2021, 05, e174-e175.	0.7	0
8	Polycythemia vera emerging eighteen years after acute myeloid leukemia diagnosis. <i>Blood Research</i> , 2021, 56, 121-123.	0.5	1
9	Prevalence of atypical BCR-ABL1 transcript types in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: implications for measurable residual disease. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 44, 130-130.	0.1	0
10	Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 90, 102593.	0.6	0
11	Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia. <i>Journal of Clinical Pathology</i> , 2021, 74, jclinpath-2020-207246.	1.0	0
12	exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm. <i>EXCLI Journal</i> , 2021, 20, 197-198.	0.5	0
13	The eosinophilic variant of chronic myeloid leukemia.. <i>EXCLI Journal</i> , 2021, 20, 1608-1609.	0.5	1
14	Philadelphia chromosome-positive acute lymphoblastic leukemia with an e14a3 BCR-ABL1 fusion: The role of molecular monitoring. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 166-167.	0.6	0
15	The role of a low erythropoietin level in the diagnosis of JAK2 exon 12-mutated polycythemia vera. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 80, 102377.	0.6	1
16	The <i>JAK2</i> V617F mutation in breast cancer?. <i>Breast Journal</i> , 2020, 26, 592-592.	0.4	0
17	Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia. <i>Leukemia Research Reports</i> , 2020, 14, 100218.	0.2	1
18	Prefibrotic Myelofibrosis Presenting with Multiple Cerebral Embolic Infarcts and the Rare MPL W515S Mutation. <i>Case Reports in Hematology</i> , 2020, 2020, 1-4.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Repeat JAK2 V617F testing in patients with suspected essential thrombocythaemia. <i>Journal of Clinical Pathology</i> , 2020, 73, 772-772.	1.0	1
20	Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia. <i>Leukemia Research Reports</i> , 2020, 13, 100195.	0.2	0
21	Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2020, 2020, 1-4.	0.3	2
22	Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?. <i>Blood Research</i> , 2020, 55, 67-68.	0.5	0
23	Strange bedfellows: NPM1 mutations in acute promyelocytic leukemia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, , .	0.6	0
24	Frequency and spectrum of atypical BCR-ABL1 transcripts in chronic myeloid leukemia. <i>Experimental Oncology</i> , 2020, 42, 78-79.	0.4	1
25	Absence of Polycythemia Vera in Postrenal Transplant Erythrocytosis. <i>Experimental and Clinical Transplantation</i> , 2020, 18, 657-658.	0.2	0
26	Concurrent chronic myeloid leukemia and -mutated myeloproliferative neoplasm. <i>EXCLI Journal</i> , 2020, 19, 86-88.	0.5	1
27	Can post-splenectomy thrombocytosis mask essential thrombocythaemia?. <i>EXCLI Journal</i> , 2020, 19, 773-774.	0.5	0
28	mutations in myeloproliferative neoplasms: An unfolding story. <i>EXCLI Journal</i> , 2020, 19, 1399-1400.	0.5	0
29	The impact of sample processing delay on deep molecular responses in chronic myeloid leukemia. <i>Irish Journal of Medical Science</i> , 2019, 188, 351-352.	0.8	0
30	Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion. <i>Case Reports in Hematology</i> , 2019, 2019, 1-4.	0.3	2
31	Sorafenib for relapsed FLT3 -positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2579-2580.	0.2	1
32	Hairy Cell Leukemia Masquerading as Pancytopenia in Pregnancy. <i>Case Reports in Hematology</i> , 2019, 2019, 1-3.	0.3	2
33	“JAK2 V617F Mutation in Cervical Cancer Related to HPV & STIs” - Letter. <i>Journal of Cancer Prevention</i> , 2019, 24, 59-60.	0.8	2
34	No indication for CALR mutation analysis in Irish patients presenting with deep vein thrombosis or pulmonary embolism. <i>Irish Journal of Medical Science</i> , 2019, 188, 1459-1460.	0.8	0
35	Aquagenic pruritus and the JAK2 V617F mutation. <i>Clinical and Experimental Dermatology</i> , 2019, 44, e33-e33.	0.6	1
36	Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis. <i>Leukemia Research</i> , 2019, 77, 28-29.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Neutrophilia and the JAK2 V617F Mutation. <i>Pathology and Oncology Research</i> , 2019, 25, 437-438.	0.9	0
38	Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia. <i>Experimental Oncology</i> , 2019, 41, 82-83.	0.4	2
39	The V617F mutation in retinal vein or artery occlusion. <i>EXCLI Journal</i> , 2019, 18, 127-128.	0.5	1
40	The mutational landscape of atypical chronic myeloid leukemia. <i>EXCLI Journal</i> , 2019, 18, 256-258.	0.5	2
41	Hypercalcemia as a biomarker of myeloproliferative neoplasms?. <i>EXCLI Journal</i> , 2019, 18, 777-778.	0.5	0
42	False-negative CALR mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action. <i>Journal of Clinical Pathology</i> , 2018, 71, 473-474.	1.0	1
43	An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanation?. <i>European Journal of Internal Medicine</i> , 2018, 52, e37-e38.	1.0	2
44	Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 98-103.	0.3	6
45	An acquired <i>NRAS</i> mutation contributes to neutrophilic progression in a patient with primary myelofibrosis. <i>British Journal of Haematology</i> , 2018, 183, 308-310.	1.2	3
46	Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. <i>Clinical and Translational Oncology</i> , 2018, 20, 420-423.	1.2	12
47	Incidental abnormal bone marrow signal on magnetic resonance imaging and reflexive testing for the JAK2 V617F mutation. <i>Quantitative Imaging in Medicine and Surgery</i> , 2018, 8, 881-882.	1.1	1
48	Double-mutant myeloproliferative neoplasms. <i>Medical Oncology</i> , 2018, 35, 137.	1.2	3
49	Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.3	0
50	Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.3	0
51	Reflective molecular testing for myeloproliferative neoplasms in patients with elevated serum vitamin B12. <i>Annals of Clinical Biochemistry</i> , 2018, 55, 717-718.	0.8	1
52	Detecting CALR mutations in splanchnic vein thrombosis: Who and how?. <i>Journal of Translational Internal Medicine</i> , 2018, 6, 55-57.	1.0	3
53	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. <i>Blood</i> , 2018, 132, 5241-5241.	0.6	0
54	The V617F mutation in isolated neutropenia. <i>EXCLI Journal</i> , 2018, 17, 1-2.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Serum ferritin as a biomarker of polycythemia vera?. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2018, 29, 94-95.	0.7	0
56	Anagrelide and the CALR mutation allele burden in essential thrombocythemia. <i>Experimental Oncology</i> , 2018, 40, 152-153.	0.4	0
57	The JAK2 V617F mutation in lung cancer: caveat emptor. <i>Experimental Oncology</i> , 2018, 40, 343-344.	0.4	0
58	Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence. <i>European Journal of Internal Medicine</i> , 2017, 40, e22-e23.	1.0	3
59	Chronic myeloid leukemia with a novel e8a1<i>BCR-ABL1</i>fusion: rapid molecular response with nilotinib. <i>Leukemia and Lymphoma</i> , 2017, 58, 2255-2257.	0.6	0
60	The JAK2 V617F mutation in patients with anaemia. <i>Irish Journal of Medical Science</i> , 2017, 186, 349-350.	0.8	0
61	The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 66-67.	0.6	1
62	Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis. <i>Journal of Clinical Pathology</i> , 2017, 70, 1089-1089.	1.0	6
63	Isolated erythrocytosis associated with a CALR mutation. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 66, 6-7.	0.6	4
64	Splenomegaly and the JAK2 V617F mutation. <i>European Journal of Internal Medicine</i> , 2017, 37, e45-e46.	1.0	1
65	Characterization of a novel variant BCRÁABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 85-88.	0.6	3
66	The JAK2 V617F mutation and thrombocytopenia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 44-45.	0.6	3
67	Chronic Myeloid Leukemia with an e6a2BCR-ABL1Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring. <i>Case Reports in Hematology</i> , 2017, 2017, 1-5.	0.3	2
68	Molecular Profiling: A Case of ZBTB16-RARAacute Promyelocytic Leukemia. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4.	0.3	5
69	Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.3	1
70	In Response to ÁBCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test RequestsÁ. <i>Journal of Oncology Practice</i> , 2017, 13, 283-284.	2.5	1
71	Molecular Investigation of a Suspected Myeloproliferative Neoplasm in Patients with Basophilia. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, EL01.	0.8	2
72	Hemochromatosis, Erythrocytosis and the p.V617F Mutation. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2017, 28, 92-93.	0.7	1

#	ARTICLE	IF	CITATIONS
73	Variant BCR-ABL1 fusion genes in adult Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. <i>EXCLI Journal</i> , 2017, 16, 1144-1147.	0.5	2
74	Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia. <i>Case Reports in Hematology</i> , 2016, 2016, 1-5.	0.3	3
75	Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches. <i>BioMed Research International</i> , 2016, 2016, 1-6.	0.9	8
76	Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics. <i>Jak-stat</i> , 2016, 5, e1248011.	2.2	11
77	CALR mutation profile in Irish patients with myeloproliferative neoplasms. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 112-115.	0.6	0
78	Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 161-163.	1.2	18
79	Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 168-169.	0.6	3
80	Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 457-461.	1.6	9
81	Capricious CALR mutated clones in myeloproliferative neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 57, 110-111.	0.6	1
82	The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis. <i>Pathology and Oncology Research</i> , 2016, 22, 229-230.	0.9	2
83	No Benefit of BCR-ABL1 Screening in Polycythemia. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, EL05.	0.8	0
84	CALR mutation analysis is not indicated in patients with splanchnic vein thrombosis without evidence of a myeloproliferative neoplasm: a micro-review. <i>Annals of Gastroenterology</i> , 2016, 29, 557-558.	0.4	4
85	Molecular diagnostics of myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2015, 95, 270-279.	1.1	67
86	Getting Hot Under the CALR: What Drives Pediatric Myeloproliferative Neoplasms?. <i>Pediatric Hematology and Oncology</i> , 2015, 32, 513-514.	0.3	0
87	Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation. <i>Case Reports in Hematology</i> , 2015, 2015, 1-4.	0.3	1
88	The e1a3 BCR-ABL1 Fusion Transcript in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Annals of Laboratory Medicine</i> , 2015, 35, 540-541.	1.2	2
89	Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 175-176.	0.8	3
90	Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion. <i>Medical Oncology</i> , 2015, 32, 452.	1.2	11

#	ARTICLE	IF	CITATIONS
91	Comment on: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 251-252.	1.6	1
92	Incidence of <i>CALR</i> mutations in patients with splanchnic vein thrombosis. <i>British Journal of Haematology</i> , 2015, 168, 459-460.	1.2	36
93	Standardized Molecular Monitoring for Variant BCR-ABL1 Transcripts in Chronic Myeloid Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 969-969.	1.2	8
94	Lack of myeloproliferative neoplasm-associated <i>CALR</i> mutations in acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1168-1169.	0.6	0
95	The JAK2 V617F Mutation in Plasma Cell Neoplasms with Co-existing Erythrocytosis. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015, 9, EL01.	0.8	2
96	Lack of National Consensus for the Molecular Investigation of Myeloproliferative Neoplasms. <i>Irish Medical Journal</i> , 2015, 108, 189-90.	0.0	1
97	JAK2 mutations to the fore in hereditary thrombocythemia. <i>Jak-stat</i> , 2014, 3, e957618.	2.2	3
98	Assessment of <i>CALR</i> mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2014, 166, 800-802.	1.2	30
99	<i>CALR</i> mutations are rare in childhood essential thrombocythemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1523-1523.	0.8	16
100	Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies. <i>Frontiers in Oncology</i> , 2014, 4, 212.	1.3	4
101	Exceptions to the rule in hairy cell leukaemia: implications for molecular diagnostics and targeted therapy. <i>Medical Oncology</i> , 2014, 31, 895.	1.2	1
102	The JAK2V617F Mutation in Pediatric Myeloproliferative Neoplasms: How and When?. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 138-139.	0.3	1
103	Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, e29-31.	1.4	7
104	Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. <i>Familial Cancer</i> , 2014, 13, 659-663.	0.9	4
105	The molecular landscape of childhood myeloproliferative neoplasms. <i>Leukemia Research</i> , 2014, 38, 997-998.	0.4	4
106	The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 843-844.	1.3	20
107	Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. <i>Leukemia Research</i> , 2014, 38, 310-315.	0.4	12
108	Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?. <i>Medical Oncology</i> , 2013, 30, 508.	1.2	13

#	ARTICLE	IF	CITATIONS
109	An immunophenotypic and molecular diagnosis of composite hairy cell leukaemia and chronic lymphocytic leukaemia. <i>Medical Oncology</i> , 2013, 30, 692.	1.2	6
110	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of <i>JAK2 V617F</i> and other relevant mutations. <i>British Journal of Haematology</i> , 2013, 160, 25-34.	1.2	87
111	BCR-ABL1 Kinase Domain Mutation Analysis in an Irish Cohort of Chronic Myeloid Leukemia Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 170-173.	0.3	3
112	Transient <i>JAK2 V617F</i> mutation in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone. <i>British Journal of Haematology</i> , 2013, 161, 297-298.	1.2	5
113	Chronic myeloid leukaemia presenting post-radiotherapy for prostate cancer: further evidence for an immunosurveillance effect. <i>British Journal of Haematology</i> , 2013, 162, 708-710.	1.2	2
114	Rapid Evolution to Blast Crisis Associated with a Q252HABL1 Kinase Domain Mutation in e19a2BCR-ABL1 Chronic Myeloid Leukaemia. <i>Case Reports in Hematology</i> , 2013, 2013, 1-4.	0.3	0
115	BRAFV600E-Negative Hairy Cell Leukaemia. <i>Case Reports in Hematology</i> , 2013, 2013, 1-3.	0.3	10
116	Nonfamilial, <i>MPL S505N</i> -Mutated Essential Thrombocythaemia. <i>Case Reports in Hematology</i> , 2013, 2013, 1-4.	0.3	3
117	A prenatal origin of childhood essential thrombocythaemia. <i>British Journal of Haematology</i> , 2013, 163, 676-678.	1.2	5
118	Chronic Myeloid Leukemia with e19a2BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring. <i>Case Reports in Hematology</i> , 2012, 2012, 1-3.	0.3	10
119	Referral centre variation in requesting <i>JAK2 V617F</i> mutation analysis for the investigation of a myeloproliferative neoplasm. <i>Journal of Clinical Pathology</i> , 2012, 65, 1149-1150.	1.0	10
120	A novel, variant <i>BCR-ABL1</i> transcript not detected by standard real-time quantitative PCR in a patient with chronic myeloid leukaemia. <i>International Journal of Laboratory Hematology</i> , 2012, 34, e1-2.	0.7	3
121	Correlation of the <i>BRAF V600E</i> mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 417-421.	0.7	20
122	Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. <i>Leukemia Research</i> , 2012, 36, 483-484.	0.4	31
123	The Incidence of Co-Existing <i>BCR-ABL1</i> and <i>JAK2 V617F</i> Rearrangements: Implications for Molecular Diagnostics. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2012, 18, 20-21.	1.2	2
124	A novel <i>BCR-ABL1</i> fusion with insertion of <i>RALGPS1</i> exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 919-921.	0.6	6
125	Guidelines for the measurement of <i>BCR-ABL1</i> transcripts in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2011, 153, 179-190.	1.2	94
126	Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, e169-e170.	0.4	12

#	ARTICLE	IF	CITATIONS
127	Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha. <i>Annals of Hematology</i> , 2011, 90, 233-234.	0.8	4
128	Acute Lymphoblastic Leukaemia with an e1a3 <i>BCR-ABL1</i> Fusion. <i>Acta Haematologica</i> , 2011, 126, 214-215.	0.7	9
129	Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, e176-e177.	0.4	0
130	Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts. <i>Leukemia Research</i> , 2010, 34, e204-e205.	0.4	11
131	A Doctor(s) dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2010, 151, 101-102.	1.2	15
132	Prevalence of the JAK2 V617F and MPL Mutations in Stroke, Abdominal and Peripheral Venous Thrombosis. <i>Acta Haematologica</i> , 2010, 124, 160-161.	0.7	5
133	Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.. <i>Blood</i> , 2010, 116, 3427-3427.	0.6	6
134	Identification of <i>MPL</i> W515L/K Mutations in Patients with Primary Myelofibrosis and Essential Thrombocythaemia by Allele-Specific Polymerase Chain Reaction. <i>Acta Haematologica</i> , 2009, 121, 221-222.	0.7	7
135	Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.. <i>Blood</i> , 2009, 114, 3294-3294.	0.6	5
136	Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end?. <i>Blood</i> , 2008, 112, 4356-4357.	0.6	12
137	Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. <i>Irish Journal of Medical Science</i> , 2007, 176, 105-109.	0.8	6
138	Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 1394-1396.	0.6	14
139	AML with t(8;21) and trisomy 4: possible involvement of c-kit?. <i>Leukemia</i> , 2003, 17, 1915-1915.	3.3	7
140	Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia. <i>Leukemia Research</i> , 2003, 27, 869-870.	0.4	7
141	Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 24-32.	1.5	53
142	The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. <i>Blood</i> , 2001, 98, 1752-1759.	0.6	1,392
143	Screening for mutations of Bcl10 in leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 611-615.	1.2	11
144	c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1999, 105, 894-900.	1.2	229

#	ARTICLE	IF	CITATIONS
145	IL-1 receptor antagonist gene polymorphism in patients with secondary acute myeloid leukaemia. <i>Cytokines, Cellular & Molecular Therapy</i> , 1998, 4, 7-9.	0.3	1
146	Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 1997, 96, 490-492.	1.2	15